Brucellosis in Man: Treatment with a New Anti-Serum

View More View Less
  • Department of Bacteriology and Hygiene, College of Medicine, University of Cincinnati, and the Cincinnati General Hospital

The anti-serums for these initial therapeutic trials were produced from goats after subcutaneous inoculations with chemically treated suspensions of Brucellae. The serums used during the first year represented 6 strains, one bovine and 5 porcine. These types were identified for us through the courtesy of Dr. Huddleson. At the beginning of the second year 5 melitensis strains were added to these six. One animal received formaldehyde-killed bacteria only; the other was inoculated with formaldehyde-killed suspensions that had subsequently been treated with nascent nitrous acid, a procedure which further “detoxifies” these bacteria and probably largely deaminizes their component proteins (1). These serums, so far as we are able to judge now, are equally effective therapeutically. The principle involved, and details of production, will be presented at some future time.

We have had to feel our way in regard to dosage. During the past year we have adopted a total amount of 60.0 cc., usually given in 3 daily injections of 20.0 cc. each, as the average adult dosage for infections of average severity.